<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013048</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-I-107</org_study_id>
    <nct_id>NCT04013048</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor</brief_title>
  <official_title>A Phase I Mass Balance and Biotransformation Study of [14C]-Fluzoparib in Chinese Patients With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]-FZPL in Chinese
      Patients with Solid Tumor
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The distribution of Fluzoparib in the whole blood and plasma and whole.radioactive pharmacokinetics following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled Fluzoparib recovered in blood and in total, up to Day 10 (approx).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of whole radioactivity of excrement of orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor to obtain the mass balance data and the main excretion pathway in human body.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled Fluzoparib recovered in urine, faeces and in total, up to Day 10 (approx).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the main metabolite and biotransformation pathway of Fluzoparib and investigation of metabolite with proportion &gt;10% in plasma following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>Proportion of different metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of the concentrations of Fluzoparib in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>The concentrations of Fluzoparib in plasma up to Day 10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observation of safety following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>Adverse events assessed by CTCAE v5.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>[14C]-Fluzoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single dose of [14C]- Fluzoparib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-Fluzoparib</intervention_name>
    <description>Patients will receive single dose of orally [14C]- Fluzoparib on Day 1.</description>
    <arm_group_label>[14C]-Fluzoparib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects diagnosed with advanced solid malignancies who are refractory or intolerant
             to standard therapy or considered to be benefit from the treatment of fluzoparib.

          2. ECOG performance status of 0 to 1.

          3. Life expectancy of more than 3 months.

          4. Signing the informed consent forms.

          5. Adequate bone marrow, liver and renal function.

          6. Be able to communicate well with the researcher and be able to complete the trial in
             accordance with the program.

        Exclusion Criteria:

          1. Subjects who take any drugs that strongly inhibit or induce the CYP450 enzyme 14 days
             prior to study drug administration；

          2. Those who have history of alcohol abuse (it was defined as that the daily alcohol
             consumption was higher than the following criteria: the weekly alcohol consumption was
             higher than 14 units of alcohol (1 unit= 360 ml beers/45 ml liquor containing 40%
             alcohol/150ml grape wine) 6 months prior to screening period, or the alcohol breath
             test results ≥20 mg/dl during screening period；

          3. Subjects who smoked daily &gt;5 sticks of cigarette 3 months prior to first dose or
             cannot give up smoking during study.

          4. Subjects who have history of drug abuse or taking soft drug (i.e., marihuana) 3 months
             prior to screening period or taking hard drugs (i.e., cocaine, amphetamines,
             benzodiazepine, etc.); or the results of urine test in drugs were positive.

          5. Subjects who were used to drink grapefruit juice or overconsumption of tea, coffee,
             and the drink with caffeine; and cannot give up them during test.

          6. Subjects who need long-term exposure to radiation, or who have been exposed to PET-CT
             or ECT within 3 months prior to study drug administration or who have participated in
             the labeling test of radiopharmaceuticals.

          7. Subjects who have fertility planning within the range of starting trial - 1 year after
             finishing trial.

          8. Subjects who have excessive bleeding or blood donation (400ml) 3 months prior to
             screening period, or planned to donate blood 1 month after finishing this trial.

          9. Subjects who have habitual constipation or diarrhea, irritable bowel syndrome,
             inflammatory bowel disease.

         10. Subjects must not have had prior treatment with PARP inhibitors.

         11. Subjects who cannot complete this study because of other reasons, or any factors
             judged by investigator that the participants cannot meet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quanren Wang, Ph.D</last_name>
    <phone>+86-18601760990</phone>
    <email>wangquanren@hrglobe.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyan Miao, Doctor</last_name>
      <phone>86-0512-67780040</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 7, 2019</study_first_submitted>
  <study_first_submitted_qc>July 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 7, 2019</last_update_submitted>
  <last_update_submitted_qc>July 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>14C-Fluzoparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

